Literature DB >> 23927393

Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma.

Nathalie Nols1, Nicolas Mounier, Salima Bouazza, Renaud Lhommel, Sabrina Costantini, Thierry Vander Borght, Marie-Christiane Vekemans, Anne Sonet, André Bosly, Lucienne Michaux, Marc André, Eric Van Den Neste.   

Abstract

The prognostic value of interim (18)fluorodeoxyglucose positron emission tomography (i-PET) was investigated in 73 patients (median age 60 years) with diffuse large B-cell lymphoma (DLBCL). i-PET was analyzed using the Deauville score (DS) and change in maximum standardized uptake value (ΔSUV(max)). Patients with a DS of 1-3 demonstrated a significantly (p < 0.0001) better outcome (median follow-up 2.4 years) than patients with a score of 4 or 5 in terms of event-free survival (EFS) (79% vs. 36%), progression-free survival (PFS) (84% vs. 47%) and overall survival (OS) (91% vs. 51%). EFS (73% vs. 42%), PFS (78% vs. 50%) and OS (88% vs. 56%) were also significantly (p = 0.023) different between patients with ΔSUV(max) > 66% or ≤ 66%. Patients (n = 33) combining a favorable age-adjusted International Prognostic Index (IPI) (0 or 1) and a negative i-PET either by DS or ΔSUV(max) criteria showed a particularly good outcome (EFS: 85%, PFS: 88%, OS: 94%). Overall, i-PET was highly and independently predictive of any outcome, and its negative predictive value was improved by combination with IPI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23927393     DOI: 10.3109/10428194.2013.831848

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  25 in total

1.  Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.

Authors:  Heiko Schöder; Andrew D Zelenetz; Paul Hamlin; Somali Gavane; Steven Horwitz; Matthew Matasar; Alison Moskowitz; Ariela Noy; Lia Palomba; Carol Portlock; David Straus; Ravinder Grewal; Jocelyn C Migliacci; Steven M Larson; Craig H Moskowitz
Journal:  J Nucl Med       Date:  2015-12-30       Impact factor: 10.057

2.  Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Authors:  Mark Hertzberg; Maher K Gandhi; Judith Trotman; Belinda Butcher; John Taper; Amanda Johnston; Devinder Gill; Shir-Jing Ho; Gavin Cull; Keith Fay; Geoff Chong; Andrew Grigg; Ian D Lewis; Sam Milliken; William Renwick; Uwe Hahn; Robin Filshie; George Kannourakis; Anne-Marie Watson; Pauline Warburton; Andrew Wirth; John F Seymour; Michael S Hofman; Rodney J Hicks
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

Review 3.  FDG PET/CT imaging as a biomarker in lymphoma.

Authors:  Michel Meignan; Emmanuel Itti; Andrea Gallamini; Anas Younes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

Review 4.  Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

Authors:  Bertrand Coiffier; Clémentine Sarkozy
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.

Authors:  David M Kurtz; Mohammad S Esfahani; Florian Scherer; Joanne Soo; Michael C Jin; Chih Long Liu; Aaron M Newman; Ulrich Dührsen; Andreas Hüttmann; Olivier Casasnovas; Jason R Westin; Matthais Ritgen; Sebastian Böttcher; Anton W Langerak; Mark Roschewski; Wyndham H Wilson; Gianluca Gaidano; Davide Rossi; Jasmin Bahlo; Michael Hallek; Robert Tibshirani; Maximilian Diehn; Ash A Alizadeh
Journal:  Cell       Date:  2019-07-04       Impact factor: 41.582

6.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

Authors:  Sally F Barrington; N George Mikhaeel; Lale Kostakoglu; Michel Meignan; Martin Hutchings; Stefan P Müeller; Lawrence H Schwartz; Emanuele Zucca; Richard I Fisher; Judith Trotman; Otto S Hoekstra; Rodney J Hicks; Michael J O'Doherty; Roland Hustinx; Alberto Biggi; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

7.  Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden.

Authors:  Sally F Barrington; Michel Meignan
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

Review 8.  FDG-PET imaging in hematological malignancies.

Authors:  L Valls; C Badve; S Avril; K Herrmann; P Faulhaber; J O'Donnell; N Avril
Journal:  Blood Rev       Date:  2016-04-16       Impact factor: 8.250

9.  Prognostic value of 18F-fluorodeoxyglucose positron emission tomography using Deauville criteria in diffuse large B cell lymphoma treated with autologous hematopoietic stem cell transplantation.

Authors:  Zhitao Ying; Lan Mi; Nina Zhou; Xuejuan Wang; Zhi Yang; Yuqin Song; Xiaopei Wang; Wen Zheng; Ningjing Lin; Meifeng Tu; Yan Xie; Lingyan Ping; Chen Zhang; Weiping Liu; Lijuan Deng; Jun Zhu
Journal:  Chin J Cancer Res       Date:  2019-02       Impact factor: 5.087

10.  Prognostic value of pre- and post-transplantation 18F-fluorodeoxyglucose positron emission tomography results in non-Hodgkin lymphoma patients receiving autologous stem cell transplantation.

Authors:  Zhitao Ying; Lan Mi; Xuejuan Wang; Yuewei Zhang; Zhi Yang; Yuqin Song; Xiaopei Wang; Wen Zheng; Ningjing Lin; Meifeng Tu; Yan Xie; Lingyan Ping; Chen Zhang; Weiping Liu; Lijuan Deng; Jun Zhu
Journal:  Chin J Cancer Res       Date:  2017-12       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.